rituximab

February 5, 2012

Ipilimumab Approval Highlights Immunotherapy Renaissance

March 25, 2011 By MD Becker Partners Leave a Comment

mab_slide

On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.

Filed Under: Articles Tagged With: AGEN, Agenus, Allovectin-7, Amgen, AMGN, Antigenics, AVAX, AVAX Technologies, AVXT.PK, Bavarian Nordic, BIIB, Biogen Idec, BiovaxID, Biovest International, BioVex, BMY, Bristol-Myers Squibb, BVTI, CancerVax, Canvaxin, CDX-110, Celldex Therapeutics, CLDX, Corixa, Dendreon, DNDN, GlaxoSmithKline plc, GMK vaccine, GSK, ipilimumab, Lucanix, MAGE-A3 ASCI, Melacine, MVAX, Novarx, Oncophage, Oncothyreon, OncoVex, ONTY, Oxford BioMedica, PGNX, Progenics Pharmaceuticals, PROSTVAC, Rituxan, rituximab, Stimuvax, TG4010, transgene, Trovax, Vical, VICL, William Coley, Yervoy

FDA Approved Monoclonal Antibodies (mAbs) for Cancer Therapy

March 5, 2011 By MD Becker Partners 3 Comments

Graph of FDA Approved Monoclonal Antibodies (mAbs) for Cancer Therapy

The following image may be reproduced without modification using the attribution “Graph source – MD Becker Partners (www.mdbpartners.com).” Click on the image to enlarge.

Filed Under: Facts & Figures Tagged With: alemtuzumab, bevacizumab, biotechnology, cancer therapy, cetuximab, FDA, gemtuzumab ozogamicin, ibrituxomab tiuxetan, ipilimumab, monoclonal antibodies, ofatumumab, panitumumab, rituximab, tositumomab, trastuzumab

Monoclonal Antibody Companies Command Premiums

July 11, 2010 By MD Becker Partners Leave a Comment

Monoclonal antibody image from MD Becker Partners

Monoclonal antibodies, which have been approved for immunological, anti-infective, ophthalmic, cancer and other categories, represent one of the most successful therapeutic drug classes. Ten monoclonal antibodies have been approved for cancer therapy alone, including three blockbuster products sold by the Roche Group (RHHBY) – Avastin® [bevacizumab], Rituxan® [rituximab], and Herceptin® [trastuzumab] that collectively represented nearly [...]

Filed Under: Articles Tagged With: Abbott, Abgenix, ABT, adalimumab, Agensys, Alexion Pharmaceuticals, ALXN, Astellas Pharma, AstraZeneca, Avastin, Bayer Schering Pharma AG, BAYRY.PK, bevacizumab, biosimilars, BMY, Bristol-Myers Squibb, Cambridge Antibody Tech, CEPH, Cephalon, Ception Therapeutics, cetuximab, Domantis, Eli Lilly & Co, Erbitux, erlotinib, Facet Biotech, FDA, GEN.CO, Genmab A/S, GENZ, Genzyme, Herceptin, HGSI, Human Genome Sciences, Humira, ImClone Systems, IMGN, IMMU, ImmunoGen, Immunomedics, Inc., infliximab, KaloBios Pharmaceuticals, LLY, mAbs, MacroGenics, MedImmune, Micromet, MITI, monoclonal antibodies, MORG.DE, Morphosys AG, Morphotek, NASDAQ Biotechnology Index, NBI, NeuTec Pharma plc, OncoMed Pharmaceuticals, OSI Pharmaceuticals, PFE, Pfizer, Regeneron, REGN, Remicade, RHHBY, Rinat Neuroscience Corp, Rituxan, rituximab, roche, sanofi-aventis Group, Seattle Genetics, SGEN, SNY, Tarceva, trastuzumab, Tufts Center for the Study of Drug Development, XOMA

Cancer Vaccine Therapies: Failures and Future Opportunities

April 7, 2010 By MD Becker Partners 3 Comments

FIGURE 1: FDA APPROVAL OF CANCER MABS FROM 1997-2010

(Note: the following text is an Executive Summary from our new 150-page report titled “Cancer Vaccine Therapies: Failures and Future Opportunities”) Since the early 1990s, cancer immunotherapy has provided hope to patients, physicians, and investors as a new treatment modality with limited side effects and superior efficacy. Cancer immunotherapy broadly includes passive immunization, active immunization, [...]

Filed Under: Articles Tagged With: active immunotherapy, AGEN, allogeneic, Allovectin-7, American Society for Clinical Oncology, Antigenics, Arzerra, ASCO, autologous, Bavarian Nordic, BIIB, Biogen Idec, Biologics License Application, biotechnology, BiovaxID, Biovest International, BMY, Bristol-Myers Squibb Company, BVTI, cancer vaccine, CD20, CDX-110, Celldex Therapeutics, CTLA-4, Dendreon, dendritic cells, DNDN, EGFRvIII, Genmab A/S, GlaxoSmithKline, GM-CSF, gp100, GSK, GVAX, immunotherapy, ipilimumab, life sciences, lung cancer, MAGE-3, MAGE-A3 ASCI, MD Becker Partners, melanoma, monoclonal antibodies, NCI, NHL, non-Hodgkin’s Lymphoma, NSCLC, ofatumumab, Oncophage, passive immunotherapy, PDUFA, PFE, Pfizer, prostate cancer, prostatic acid phosphatase, PROSTVAC, Provenge, RHHBY, Rituxan, rituximab, Roche Group, sipuleucel-T, TRICOM, vaccine, Vical, VICL